Why the study?
Is the GSTM1 null variant associated with anthracycline-associated heart toxicity in pediatric cancer survivors?
Is the GSTM1 null variant associated with anthracycline-associated heart toxicity in pediatric cancer survivors?
Answers are grounded in this paper and cite their sources.
This editorial highlights the association between the GSTM1 null variant and anthracycline-induced cardiomyopathy in pediatric cancer survivors.
Anthracyclines are an important chemotherapeutic agent in the treatment of many childhood cancers, but their use is associated with a significant rate of cardiomyopathy in survivors. This editorial discusses an article in this issue of Cancer by Singh and colleagues, who have found an association of the GSTM1 null variant with anthracycline‐associated heart toxicity.
No takes yet. Share an insight, caveat, or question.
Shahrad R. Rassekh (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: